Evaluating the effectiveness and safety of AD-218 for mixed dyslipidemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the efficacy and safety of the drug AD-218 in patients with mixed dyslipidemia. Participants will receive either AD-218, AD-218A, or a placebo to determine the drug's impact on lipid levels and overall health. The study will involve individuals over 19 years old who meet specific inclusion criteria and will exclude those with certain medical histories. The trial is designed to provide robust data on the effectiveness of AD-218 in managing mixed dyslipidemia.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* A man or woman over 19 years old.
* Sign on ICF prior to study participation

Exclusion Criteria:

* History of Fibromyalgia, Myopathy etc (CK ≥ 2 X ULN)
* Other exclusions applied

Where it's running

• Yeongnam University Hospital
  Daegu, Nam-gu, South Korea Recruiting

Study contacts

• Principal investigator: Kyu Chang Won, M.D., Ph.D — Yeungnam University Hospital
• Study coordinator: Sarah Yoon
• Email: sryoon@addpharma.co.kr
• Phone: 82-031-891-5576

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MWX203: a medicine for mixed dyslipidemia given alone or with Inclisiran

  This phase 2 study tests MWX203 alone or with Inclisiran in adults with mixed dyslipidemia who don’t reach lipid goals on statins.

  Recruiting Phase 2 Shanghai Minwei Biotechnology Co., Ltd · Beijing, Beijing Municipality · NCT07803822

• Obicetrapib vs. bempedoic acid for high-risk high cholesterol patients

  This phase 3 study tests whether obicetrapib can lower LDL-C more than bempedoic acid in adults with primary non-familial hypercholesterolemia or mixed dyslipidemia who still have high LDL-C despite maximum tolerated therapy.

  Recruiting Phase 3 A. Menarini International Licensing S.A. · Stockton-on-Tees · NCT07614958

• Bempedoic Acid With Ezetiimibe in Adults with High Cholesterol or Mixed Dyslipidemia

  This study tests bempedoic acid alone or with ezetimibe in real-world adults with primary hypercholesterolemia or mixed dyslipidemia to see how safe and effective it is in routine care.

  Recruiting at 38 sites Daiichi Sankyo · Belo Horizonte and 37 other locations · NCT07206472

• Comparing the effects of two medications on healthy individuals

  This study tests how two medications work in healthy people to see if one is safer or more effective than the other.

  Recruiting Phase 1 Addpharma Inc. · Seoul · NCT06932705

• Evaluating the effectiveness and safety of a combination medication for cholesterol management

  This study is testing a new combination medication for cholesterol management to see if it works better and is safe for people who need a change in their current cholesterol treatment.

  Recruiting Boryung Pharmaceutical Co., Ltd · Seoul · NCT06314919

• Leqvio (inclisiran) post-marketing surveillance in Korea

  This will see if Leqvio (inclisiran) is safe and lowers LDL cholesterol for adults in Korea with primary hypercholesterolemia or mixed dyslipidemia who are prescribed it in routine care.

  Recruiting at 4 sites Novartis · Yangsan, Gyeongsangnam-do and 3 other locations · NCT06770543

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.